These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11712399)

  • 1. [Insulin aspart(NN-X14)].
    Namba M
    Nihon Rinsho; 2001 Nov; 59(11):2144-50. PubMed ID: 11712399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB
    Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
    Danne T; Råstam J; Odendahl R; Näke A; Schimmel U; Szczepanski R; Moeller J; Deiss D
    Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
    Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U; Ashwell SG; Home PD
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
    Pala L; Mannucci E; Dicembrini I; Rotella CM
    Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
    Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus.
    Reynolds NA; Wagstaff AJ
    Drugs; 2004; 64(17):1957-74. PubMed ID: 15329046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin therapy in type 2 diabetes: what is the evidence?
    van Avendonk MJ; Rutten GE
    Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K; Bogoev M; Raz I; Leth G; Gall MA; Hâncu N
    Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin formulations--a review.
    Gualandi-Signorini AM; Giorgi G
    Eur Rev Med Pharmacol Sci; 2001; 5(3):73-83. PubMed ID: 12004916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
    Gredal C; Rosenfalck A; Dejgaard A; Hilsted J
    Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biotechnological and administration innovations in insulin therapy].
    Verge D
    Med Sci (Paris); 2004 Nov; 20(11):986-98. PubMed ID: 15525494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.